Oneness Biotech Co., Ltd. (合一生技股份有限公司) (Taiwan, China)

1. Established in Jun. 2008, Oneness Biotech Co., Ltd. is mainly engaged in drug research and development. It issued its stock in Mar. 2009. 2. The main shareholders are A. Zhongtian Biotech, which holds 38% of the stock, takes one seat of one director. B. After Oneness Biotech Co., Ltd. was set up, Zhontian Biotech sold 60% of its stock and introduced into fund of Runtai Group. 3. Operating Overview: A. R & D project: WH-1 diabetes, wound healing drugs (expected completion in 2010 Phase II), WH-2 chronic wound healing drugs, RA-1 rheumatoid arthritis drugs B. Technical Background: a. the introduction of a therapeutic monoclonal antibody and related screening technology platform. b. In addition to R & D center, it still cooperated with Central Academia, Institute for Biotechnology Development Center, Taipei Rongmin Hospital, National Defense Medical Hospital and CRO. c. R & D staff: 1 Director, Shen Li Ming, Ph.D. Ohio State Biochemical, Director of drug development program. He has 14 years of experience in the industry. 2 Director, Pan Zonglong, Ohio Youngstown State MBA, Director of Biotech Oncology Department / Overseas Office / Division of Business Development. He has 24 years of experience in the industry-There are another two research nurses and a Commissioner. R & D costs 5.6 million, accounting for 140% of. revenue.